Mary Luu

Featured in: Favicon

Articles

Proteomics based selection achieves complete response to HER2 therapy in HER2 IHC 0 breast cancer - npj Precision Oncology

Sep 13, 2024 | nature.com | Laura Johnston |Allison Hunt |Thomas P Conrads |Mary Luu

AbstractRecent trials have shown the efficacy of trastuzumab deruxtecan (T-DXd) in HER2-negative patients, but there is not yet a way to identify which patients will best respond, especially with the inability of current HER2 IHC and FISH assays to accurately determine HER2 expression in the unamplified setting.

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.